Telavancin: A novel lipoglycopeptide antibiotic with dual mechanisms of action

Formulary

Volumn 42, Issue 9, 2007, Pages 545-557

  Knechtel, Stephanie A ^a   Jacobs, Carrie ^b   Klepser, Michael E ^c  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b PURDUE UNIVERSITY   (United States)

^c FERRIS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLOXACILLIN; DALBAVANCIN; DAPTOMYCIN; GLYCOPEPTIDE; LINEZOLID; MOXIFLOXACIN; NAFCILLIN; ORTIVANCIN; PENICILLIN DERIVATIVE; PEPTIDOGLYCAN; TELAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL MEMBRANE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUSHING; HEADACHE; HUMAN; HYPOKALEMIA; IN VITRO STUDY; INJECTION SITE REACTION; INSOMNIA; MACULOPAPULAR RASH; MENTAL DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PATHOGENESIS; PERIORBITAL EDEMA; PNEUMONIA; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; TREATMENT DURATION; URINARY EXCRETION; URTICARIA; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

EID: 35048882050     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Kuehnert MJ, Hill HA, Kupronis BA, Tokars JI, Solomon SL, Jernigan DB. Methicillin-resistant-Staphylococcus aureus hospitalizations, United States. Emerg Infect Dis. 2005;11:868-872.
2. Baquero F. Gram-positive resistance: Challenge for the development of new antibiotics. J Antimicrob Chemother. 1997;39(suppl A): 1-6.
3. Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother. 2004;38:1377-1382.
4. Small PM, Chambers HF. Vancomycin for Staphyhcoccus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother. 1990;34:1227-1231.
5. Cantoni L, Glauser MP, Bille J. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother. 1990;34:2348-2353.
6. Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49:1127-1134.
7. Pace JL, Judice JK. Telavancin (Theravance). Curr Opin Investig Drugs. 2005;6:216-225.
8. Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother. 2004;48:3043-3050.
9. Sahm DF, Benton BM, Cohen MA, et al. Telavancin demonstrates a low potential for in vitro selection of resistance among key target gram-positive species [abstract]. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, CA. Abstract C1-681.
10. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother. 2005;49:195-201.
11. Barriere S, Shaw JP, Seroogy J, Spencer E, Kitt M. Pharmacokinetics (PK) & safety of a new antibacterial, TD-6424 (TD), in healthy subjects [abstract]. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL. Abstract A-20.
12. Kaniga K, Johnston D, Wu T, et al. Effect of human serum on time-kill curves, minimum inhibitory and bactericidal concentrations of TD-6424 against staphylococci and enterococci [abstract] . Presented at: 43rd Intersciencc Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL. Abstract C1-1632.
13. Sun HK, Duchin K, Nightingale CH, Shaw J-P, Seroogy J, Nicolau DP. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother. 2006;50:788-790.
14. Gotfried M, Duchin K, Shaw J, et al. Telavancin (TLV) penetrates well into human pulmonary epithelial lining fluid (ELF) and alveolar macrophages (AM) and is unaffected by pulmonary surfactant [abstract]. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC. Abstract A-14.
15. Duchin K, Shaw J, Spencer F, Seroogy J, Barriere S, Wilbraham D. Single dose pharmacokinetics (PK) of telavancin (TLV) in healthy elderly subjects [abstract]. Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases; May 1-4, 2004; Prague, Czech Republic. Abstract P1027.
16. Duchin K, Shaw J, Spencer E, Seroogy J, Barriere S, Wilbraham D. Single dose pharmacokinetics (PK) of telavancin (TLV) in subjects with renal dysfunction [abstract]. Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases; May 1-4, 2004; Prague, Czech Republic. Abstract P1028.
17. Wong SL, Shaw JP, Bereriere S, Kitt M, Goldberg M. Pharmacokinetics of intravenous telavancin in subjects with hepatic impairment [abstract]. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, CA. Abstract A-1951.
18. Draghi DC Jones ME, Flamm RK, Thornsberry C, Sahm DF. Telavancin activity against current and diverse populations of enterococci and Streptococcus pneumoniae [abstract]. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC. Abstract E-1747.
19. Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006;58:338-343.
20. King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against gram-positive bacteria. J Antimicrob Chemother. 2004;53:797-803.
21. Laohavaleeson S, Kuti JL, Nicolau DP, Telavancin: A novel lipoglycopeptide for serious gram-positive infections. Expert Opin Investig Drugs. 2007;16:347-357.
22. Draghi DC, Jones ME, Thornsberry C, Flamm RK, Sahm DF. Telavancin activity against current and diverse Staphylococcus aureus populations [abstract]. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005;Washington, DC. Abstract E-1744.
23. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother. 2004;48:2149-2152.
24. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Inject Dis. 2005;40:1601-1607.
25. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006;5:862-867.
26. Corey GR, Stryjewski ME, O'Riordan WD, et al; for the ATLAS Study Group. ATLAS 1: The first phase 3 study evaluating the new lipoglycopeptide, telavancin, for the treatment of patients with complicated skin and skin structure infections. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases; March 31-April 4, 2007; Munich, Germany. Abstract 1733-343.
27. Corey GR, Stryjewski MH, Fowler VG Jr, et al; for the ATLAS Study Group. ATLAS 2: A double-blind, randomised, active controlled, multinational phase 3 study comparing telavancin with vancomycin for the treatment of patients with complicated skin and skin structure infections. Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases; March 31-April 4, 2007; Munich, Germany. Abstract 1733-344.
28. Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol. 2004;44:689-695.